Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement
Segments

Common Size IS
Op Efficiency
Credit Analysis

PharmaCyte Biotech, Inc. (NVLX)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
  Older >>
In millions, except per share itemsApr-30-22Apr-30-21Apr-30-20Apr-30-19Apr-30-18Apr-30-17Apr-30-16Apr-30-15
   10-K10-K10-K10-K10-K10-K10-K10-K
Total revenues  0.00.00.00.00.00.00.00.0
Cost of goods sold  1.51.41.61.62.22.01.96.5
Gross profit  -1.5-1.4-1.6-1.6-2.2-2.0-1.9-6.5
            Gross margin          
Selling, general and administrative   [+]1.91.01.61.72.41.22.73.3
Research and development  0.70.90.30.52.01.21.43.5
Other operating expenses  0.30.30.30.40.30.10.00.0
EBITDA   [+]        
Depreciation and amortization          
EBIT   [+]-4.4-3.6-3.8-4.1-7.0-4.4-6.1-13.3
            EBIT margin          
Interest income, net   [+]0.20.00.0  0.00.00.0
Other income (expense), net   [+]0.00.10.00.00.2 0.03.3
Pre-tax income  -4.2-3.6-3.8-4.1-6.8-4.4-6.1-9.9
Income taxes  0.00.00.00.00.00.00.00.0
            Tax rate  0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income  -4.2-3.6-3.8-4.1-6.8-4.4-6.1-9.9
            Net margin          
   
Basic EPS   [+]($0.27)($2.45)($4.23)$0.00($0.01)($0.01)($0.01)($0.01)
Diluted EPS   [+]($0.27)($2.45)($4.23)$0.00($0.01)($0.01)($0.01)($0.01)
   
Shares outstanding (basic)   [+]15.51.40.91,100.1968.6845.3752.4704.3
Shares outstanding (diluted)   [+]15.51.40.91,100.1968.6845.3752.4704.3
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy